4 active not recruiting. 4 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Active not recruiting 4 |
| Phase 2 | 3 | Active not recruiting 3 |
Follow Chronic Hepatitis B: new trials by email Literature Review of Chronic Hepatitis B trials Research Report on Chronic Hepatitis B
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection HT-101, HT-102 - Chronic Hepatitis B | Phase 1 / Phase 2 | Active not recruiting | Suzhou HepaThera Biotech Co., Ltd. | 86 | 2024-12-30 | 2026-10-29 |
| A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B Placebo, TQA3605 tablets, Entecavir dispersible tablets - Chronic Hepatitis b | Phase 1 / Phase 2 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 88 | 2023-12-07 | 2024-11-14 |
| Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104 ISA104, Placebo - Chronic Hepatitis b | Phase 1 / Phase 2 | Active not recruiting | Erasmus Medical Center | 24 | 2023-08-04 | 2026-09-15 |
| A Study of LP-128 Capsules in Healthy Subjects LP-128 capsules, Matching Placebo - Chronic Hepatitis b | Phase 1 | Active not recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 104 | 2021-11-19 | 2025-04-03 |
Blood-Borne Infections (4) · Chronic Disease (4) · Communicable Diseases (4) · DNA Virus Infections (4) · Digestive System Diseases (4) · Disease Attributes (4) · Hepadnaviridae Infections (4) · Hepatitis (4) · Hepatitis B (4) · Hepatitis, Chronic (4) · Hepatitis, Viral, Human (4) · Infections (4) · Liver Diseases (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Erasmus Medical Center (1) · Guangzhou Lupeng Pharmaceutical Company LTD. (1) · Suzhou HepaThera Biotech Co., Ltd. (1)
China (3) · Netherlands (1)
Chongyuan Xu, MD, PhD (1) · Dave Sprengers, MD, PhD (1)